ZURICHNovartis AG Monday said a latestage study showed little difference between its topselling Gilenya drug and a placebo for treating a difficult form of multiple sclerosis Baselbased Novartis said the Phase III trial of the treatment which is already approved for treating relapsing multiple sclerosis failed to show significant difference
  